A COPD Screening Shift Could Bring Better Therapies
A re-prioritization of disease monitoring and screening could help physicians better understand how one of the greatest killers in the US could be combated.
Related Articles
FDA News Recap: 5 Approvals to Know from the First Half of 2025
Discover groundbreaking FDA approvals in 2025 that redefine treatment standards, enhance patient care, and address critical public health needs.
Significance of AAD Guideline Updates for Atopic Dermatitis, with Robert Sidbury, MD, MPH
Following the AAD guideline update on atopic dermatitis treatments, Sidbury speaks to the significance of the guideline recommendations for patients and clinicians.
Rilparencel Improves eGFR Slope in Phase 2 CKD, Diabetes REGEN-007 Trial
Positive topline results showed patients who received 2 scheduled rilparencel injections experienced significant eGFR slope decline improvement.
Journal Review of New Medications, Recent Guidelines in Dermatology
In this session at SDPA, Griffith and Sebat review clinically relevant articles from the prior 12 months from the top dermatology journals.
Ruxolitinib Cream Shows Long-Term Safety in Children, Adults With AD, Vitiligo
Phase 3 trials have shown low rates of serious adverse events with ruxolitinib cream in pediatric and adult patients with atopic dermatitis and non-segmental vitiligo.
Ruxolitinib Cream Shows Long-Term Safety in Children, Adults With AD, Vitiligo
Phase 3 trials have shown low rates of serious adverse events with ruxolitinib cream in pediatric and adult patients with atopic dermatitis and non-segmental vitiligo.
FDA News Recap: 5 Approvals to Know from the First Half of 2025
Discover groundbreaking FDA approvals in 2025 that redefine treatment standards, enhance patient care, and address critical public health needs.
Journal Review of New Medications, Recent Guidelines in Dermatology
In this session at SDPA, Griffith and Sebat review clinically relevant articles from the prior 12 months from the top dermatology journals.
FDA News Recap: Novel Drug Approvals in First Half of 2025
A review of the 16 novel drugs approved by the US Food and Drug Administration during the first half of 2025, with links to coverage…
Review Highlights Most Effective HS Therapies Based on HiSCR-50 Responses
These data point to several hidradenitis suppurativa drugs as most impactful for those with moderate-to-severe disease, based on Hidradenitis Suppurativa Clinical Response.